Xintela
Logotype for Xintela

Xintela (XINT) investor relations material

Xintela Q4 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Xintela
Q4 2025 earnings summary27 Feb, 2026

Executive summary

  • Clinical studies with XSTEM for knee osteoarthritis and difficult-to-heal leg ulcers have been completed, showing strong safety and efficacy results, including disease-modifying potential in osteoarthritis patients.

  • Targinta, the oncology subsidiary, entered a collaboration with Memorial Sloan Kettering Cancer Center for clinical development of integrin a10β1-targeted antibodies for aggressive sarcoma.

  • GMP operations continue to generate revenue through collaborations and are positioned for self-sufficiency.

  • Rights issue and loan financing raised approximately SEK 62 million to support ongoing operations and development.

Financial highlights

  • Q4 2025 income was TSEK 415, down from TSEK 1,090 in Q4 2024; full-year income was TSEK 2,282, down from TSEK 4,215.

  • Q4 2025 loss before tax was TSEK 17,343 (Q4 2024: loss of TSEK 11,712); full-year loss before tax was TSEK 50,158 (2024: loss of TSEK 41,534).

  • Loss per share for Q4 and full year remained at SEK 0.02 and SEK 0.07, respectively.

  • Cash and cash equivalents at year-end were TSEK 23,208, up from TSEK 16,680 the previous year.

Outlook and guidance

  • Next clinical study with XSTEM in osteoarthritis patients is being prepared, with ongoing discussions for investigator-initiated studies in Europe.

  • Results from the leg ulcer study are expected by the end of May, with plans for a phase II study in collaboration with the Burn Center in Linköping.

  • Business development efforts are focused on securing partnerships and licensing deals for XSTEM and Targinta's oncology assets.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Xintela earnings date

Logotype for Xintela
Q1 202629 May, 2026
Xintela
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Xintela earnings date

Logotype for Xintela
Q1 202629 May, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Xintela AB is a Sweden-based biomedical company specializing in regenerative medicine and cancer treatments. The company focuses on developing therapies for cartilage damage and osteoarthritis using its proprietary XINMARK technology, which identifies specific stem cells that can develop into cartilage cells. In oncology, Xintela is working on targeted treatments for aggressive cancers, including glioblastoma. Through its subsidiary Targinta, the company also develops antibody-based therapies targeting cancer cells. The company is headquartered in Lund, Sweden, and its shares are listed on the Nasdaq Stockholm.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage